دورية أكاديمية
أعرض في EDS

Mesalazine in the Treatment of Extensive Alopecia Areata: A New Therapeutic Option?

التفاصيل البيبلوغرافية
العنوان: Mesalazine in the Treatment of Extensive Alopecia Areata: A New Therapeutic Option?
المؤلفون: Kiszewski AE; Department of Internal Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.; Pediatric Dermatology Unit, Hospital da Criança Santo Antônio Santa Casa de Misericórdia de Porto Alegre (ISCMPA), Porto Alegre, RS, Brazil., Bevilaqua M; Dermatology Service, ISCMPA, Porto Alegre, RS, Brazil., De Abreu LB; Section of Dermatology, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande Do Sul, Porto Alegre, RS, Brazil.
المصدر: International journal of trichology [Int J Trichology] 2018 May-Jun; Vol. 10 (3), pp. 99-102.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Publications Country of Publication: India NLM ID: 101534370 Publication Model: Print Cited Medium: Print ISSN: 0974-7753 (Print) Linking ISSN: 09747753 NLM ISO Abbreviation: Int J Trichology Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Mumbai : Medknow Publications
مستخلص: Background: Alopecia areata (AA) is a T-lymphocyte-mediated disease that results in alopecia plaques or diffuses alopecia on the scalp and body. Etiologic factors include genetic and autoimmune susceptibility. Treatment modalities are usually considered according to the extent of hair loss and the patient's age. Since there is no approved treatment by the US Food and Drug Administration, treatment options and combinations available are off-label. Patients with extensive AA (including totalis and universalis) have a low rate of spontaneous remission and poor treatment response. Extensive AA is usually associated with severe emotional distress, social discomfort, bullying, and other psychological problems for the child and family. In this context, the need for new therapeutic schemes is clear.
Materials and Methods: We retrospectively analyzed five patients (aged 2-17 years) with extensive and refractory AA who were treated with mesalazine associated or not with oral prednisolone and topical betamethasone/minoxidil.
Results: We observed complete growth of terminal hair in all patients. No patient had abnormal laboratory results or manifested drug side effects.
Conclusions: In extensive and refractory AA cases, the topical treatment combined with mesalazine may provide excellent results, reducing the need for extended oral corticosteroids courses. Besides that, mesalazine seems to minimize relapses on discontinuation of oral steroids. Controlled studies are needed to confirm the effectiveness of this combination.
Competing Interests: There are no conflicts of interest.
References: Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):611-3. (PMID: 19171984)
J Am Acad Dermatol. 2010 Feb;62(2):177-88, quiz 189-90. (PMID: 20115945)
J Investig Dermatol Symp Proc. 2018 Jan;19(1):S9-S11. (PMID: 29273111)
J Am Acad Dermatol. 2007 Oct;57(4):703-6. (PMID: 17610992)
Inflamm Bowel Dis. 2004 Sep;10(5):626-31. (PMID: 15472525)
Pediatr Ann. 2009 Jul;38(7):388-95. (PMID: 19685659)
Int J Dermatol. 2008 Aug;47(8):850-2. (PMID: 18717871)
J Am Acad Dermatol. 2004 Sep;51(3):440-7. (PMID: 15337988)
Ther Clin Risk Manag. 2007 Oct;3(5):893-903. (PMID: 18473013)
J Am Acad Dermatol. 2010 Feb;62(2):191-202, quiz 203-4. (PMID: 20115946)
فهرسة مساهمة: Keywords: Alopecia areata; aminosalicylates; mesalazine; sulfasalazine
تواريخ الأحداث: Date Created: 20180724 Latest Revision: 20220318
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6029002
DOI: 10.4103/ijt.ijt_14_18
PMID: 30034187
قاعدة البيانات: MEDLINE
الوصف
تدمد:0974-7753
DOI:10.4103/ijt.ijt_14_18